Diffuse large B cell lymphoma laboratory tests

Jump to navigation Jump to search

Diffuse large B cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diffuse large B cell lymphoma laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diffuse large B cell lymphoma laboratory tests

CDC on Diffuse large B cell lymphoma laboratory tests

Diffuse large B cell lymphoma laboratory tests in the news

Blogs on Diffuse large B cell lymphoma laboratory tests

Directions to Hospitals Treating Diffuse large B cell lymphoma

Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laboratory tests helpful in the diagnosis of diffuse large B cell lymphoma include complete blood count, LDH, and lymph node biopsy

Laboratory Tests

Laboratory studies include[1]

  • Complete blood count
  • Serum lactate dehydrogenase (LDH)
  • Comprehensive metabolic panel
  • Lymph node or extranodal tissue biopsy
  • CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency)
  • MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used
  • Bone marrow biopsy with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred
  • Hepatitis B testing prior to initiation of treatment in all patients who will receive anti CD20 monoclonal antibody-based regimens and anyone with a risk factor
  • Hepatitis C testing is needed in high-risk patients

References

  1. "Non-Hodgkin's Lymphomas (NCCN.org)" (PDF).


Template:WikiDoc Sources